【product description】
Crizotinib is an ATP-competitive multi-target protein kinase inhibitor developed by Pfizer of the United States that inhibits ALK/ROS1/Met. There is a significant clinical effect. In February 2013, Crizotinib ( trade name in Chinese) was approved by the China Food and Drug Administration (SFDA) for import.
【Indications】
Crizotinib is a kinase inhibitor used to treat
- Patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are positive for anaplastic lymphoma kinase (ALK) or ROS1 as tested by an FDA-approved test
- Pediatric and adult patients 1 year of age and older with ALK-positive relapsed or refractory systemic anaplastic large cell lymphoma (ALCL)
[Usage and Dosage]
Metastatic non-small cell lung cancer (NSCLC): 250mg orally, twice a day, until the disease progresses or the patient cannot tolerate it
- Systemic anaplastic large cell lymphoma (ALCL): The recommended dose is 280 mg/m² based on body surface area, orally, twice a day. See full prescribing information for indications for dose adjustments in patients with moderate to severe hepatic impairment or severe renal impairment
Swallow the capsule whole, do not chew, do not dissolve, do not open the capsule
May be taken with or without food; not with grapefruit juice
商品評價
目前沒有評價。